Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GT Biopharma ( (GTBP) ) just unveiled an update.
On September 16, 2024, Dr. Jeffrey Miller transitioned from his dual role as Consulting Chief Medical Officer and Chief Scientific Officer to become the Consulting Senior Medical Director for the same company. This change aligns with the University of Minnesota’s conflict of interest policies, as Dr. Miller is employed by the university, which is poised to conduct a Phase I clinical trial of the company’s new GTB-3650 compound.
For a thorough assessment of GTBP stock, go to TipRanks’ Stock Analysis page.